October 17 Earnings: Johnson&Johnson- Generic Competition Galore
Updated
Johnson & Johnson has been on an impressive intra-quarterly run with solid performance across major segments.
Strengths in the company's performance are to be driven by:
-Imbruvica and Darzalex should continue to perform well. Meaningful improvement from Stelara and Xarelto.
-New product launches like Tremfy (approved in the US late 2017 for plaque psoriasis)
-Revenue contribution from Swiss biotech Actelion, which J&J bought in June.
-Medical devices segment is expected to continue its strong growth trajectory with new product launches.
Weaknesses for the quarter are expected to be:
-Key arthritis drug Remicade to remain under pressure from generic competition.
-Invokana hurting from higher managed care discounting.
-Sluggish FDA review requiring more information before approving new drug treatments.
-Lawsuit from Pfizer to be clarified during the conference call.
Overall, I believe high expenses and generic competition will overcome the positives for the quarter.
I'm starting Johnson&Johnson with a $130 PT for the post earnings move with a tight but flexible 2.5% stop.
Strengths in the company's performance are to be driven by:
-Imbruvica and Darzalex should continue to perform well. Meaningful improvement from Stelara and Xarelto.
-New product launches like Tremfy (approved in the US late 2017 for plaque psoriasis)
-Revenue contribution from Swiss biotech Actelion, which J&J bought in June.
-Medical devices segment is expected to continue its strong growth trajectory with new product launches.
Weaknesses for the quarter are expected to be:
-Key arthritis drug Remicade to remain under pressure from generic competition.
-Invokana hurting from higher managed care discounting.
-Sluggish FDA review requiring more information before approving new drug treatments.
-Lawsuit from Pfizer to be clarified during the conference call.
Overall, I believe high expenses and generic competition will overcome the positives for the quarter.
I'm starting Johnson&Johnson with a $130 PT for the post earnings move with a tight but flexible 2.5% stop.
Note
Johnson&Johnson 
JNJ reports EPS of $1.90 on Revenue of 19.7B, beating expectations. Share are up 1.23% in Pre Market
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.